eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
2/2020
vol. 24
 
Share:
Share:
more
 
 
abstract:
Original paper

Clinicopathological characteristics of breast cancer patients with NOD2 mutation according to age

Joanna Huszno
1
,
Zofia Kolosza
2
,
Marta Nycz-Bochenek
1
,
Małgorzata Lisik
1
,
Magdalena Mazur
3
,
Jolanta Pamuła-Piłat
3
,
Ewa Grzybowska
4

1.
Genetic Outpatient Clinic, Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland
2.
Department of Biostatistics and Bioinformatics, Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland
3.
Department of Genetic and Molecular Diagnostics of Cancer, Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland
4.
Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland
Contemp Oncol (Pozn) 2020; 24 (2): 79-86
Online publish date: 2020/07/03
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
The purpose of the present study was to characterise patients with breast cancer (BC) and NOD2-mutation (age ≥ 50 years) according to their clinicopathological factors or family history. Patients aged ≥ 50 years were compared with the control group and with NOD2-mutation carriers aged < 50 years.

Material and methods
Prognostic factors were analysed in patients with BC with confirmed NOD2 c.3016_3017insC (n = 150) mutations. The control group was selected from patients with BC without mutations (n = 376).

Results
There were significant differences between NOD2-mutation carriers and the control group aged ≥ 50 years, according to HER2 overexpression (p = 0.0001), ER (–) (p = 0.007), PR (–) (p = 0.003), T1–T2 (p = 0.011), and G3 (p = 0.036). Similarly, significant differences were observed between NOD2-mutation carriers and the control group aged < 50 years, according to HER2 overexpression (p = 0.0001), ER (–) (p = 0.049), and N (+) (p = 0.038). In patients aged ≥ 50 years, family history of cancer, including BC, was observed more often in NOD2-mutation carriers compared with the control group of patients (OR = 1.66; p = 0.072, for BC in family history: OR = 2.65; p = 0.002). NOD2-mutation carriers aged ≥ 50 years had significantly less frequent G3 (p = 0.004) and HER2 overexpression (p = 0.043) compared with patients with NOD2 mutation aged < 50 years.

Conclusions
The presence of the NOD2 mutation is not only characteristic of younger patients but also in patients > 50 years of age. In NOD2-mutation carriers aged ≥ 50 years, the presence of larger tumour size, G3, or HER2 overexpression were lower compared with younger patients with NOD2 mutation.

keywords:

breast cancer, NOD2 mutation, family history of cancer

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe